Testosterone therapy for women
Testosterone therapy for women prescribes low-dose transdermal testosterone, typically a fraction of the male dose, in perimenopause and postmenopause. The 2019 Global Consensus Position Statement endorsed by eleven international societies supports a single evidence-based indication, hypoactive sexual desire disorder in postmenopausal women, and does not support the energy, mood, cognition or bone claims commonly marketed. Most prescribing is off-label because few markets license a female product. In the Atlas the reliable marker of a genuine service line is a separate published price, as at Menopause Care in the United Kingdom and wexxeljahre in Germany. Evidence tier: emerging.
What it is
Testosterone therapy for women is the prescription of testosterone, usually as a transdermal cream or gel at a fraction of the male dose, to women in perimenopause and postmenopause. It has moved out of being a footnote inside hormone therapy and become a separately named and separately priced service line, which is the evidence that operators treat it as a distinct delivered service rather than a dose adjustment. The 2019 Global Consensus Position Statement, endorsed by eleven international societies, is unambiguous about where the evidence sits: the only evidence-based indication is the treatment of postmenopausal women diagnosed with hypoactive sexual desire disorder. Benefits claimed for energy, mood, cognition, muscle mass and bone density are not supported by the consensus at the level required for a clinical indication. Much of the market nonetheless prescribes beyond that boundary, and in most jurisdictions there is no licensed female testosterone product, so prescribing is off-label using male formulations at reduced dose or, in a minority of markets, a licensed female preparation. The Atlas records the term because the delivery is real and recurring, and records the evidence tier as emerging because the indication supported by consensus is much narrower than the indication marketed.
Who it is for
Postmenopausal women with hypoactive sexual desire disorder, diagnosed clinically, are the population the international consensus supports. Beyond that the picture is unsettled: many operators offer it for fatigue, low mood, brain fog and reduced muscle strength, and some women report benefit, but the consensus statement holds that the trial evidence does not currently support those indications. Blood testosterone measurement is used to exclude supraphysiological dosing rather than to diagnose deficiency, since no female testosterone threshold defines a deficiency state. Women with androgen-sensitive conditions, and those seeking treatment premenopausally, sit outside the evidence entirely.
What to expect
Assessment typically covers sexual function history, a general hormone panel and baseline total testosterone and SHBG. Where prescribed, delivery is almost always transdermal, using a licensed male gel or cream at roughly one tenth to one twentieth of the male dose, or a licensed female product where one exists. Monitoring aims to keep levels in the premenopausal physiological range rather than to reach a target, with review at three to six months and blood testing to exclude excess. Side effects at physiological dose are usually limited to local hair growth or acne; supraphysiological dosing risks voice change and hirsutism, which may not fully reverse. Across the Atlas the separate price point is the reliable marker of a real service line: Menopause Care in the United Kingdom runs a dedicated testosterone clinic with its own consultation fee, and wexxeljahre in Germany sells a Testosteronsprechstunde as a distinct bookable appointment.
History and background
Testosterone was used in women's medicine intermittently through the mid twentieth century, often in combined implants, then largely fell out of mainstream practice. Interest revived in the 2000s around female sexual dysfunction, and a licensed transdermal patch for postmenopausal HSDD reached the European market before being withdrawn commercially. The 2019 Global Consensus Position Statement, developed across eleven societies including the International Menopause Society and the Endocrine Society, consolidated the evidence and drew the HSDD boundary explicitly. Since then the practical picture has been shaped less by new trials than by supply: the absence of licensed female products in most markets means off-label prescribing from male formulations is the norm, which in turn has made specialist private clinics the main delivery channel and pushed the service into its own priced line.
Worth knowing
The separate price is the diagnostic. A clinic that folds testosterone into a general hormone consultation is treating it as a dose decision; a clinic that sells a dedicated testosterone appointment has built a service around it, and that is what makes it a modality rather than a footnote. The prescribing is almost entirely off-label in most markets, which is unusual for a therapy this widely marketed, and it means dose accuracy depends on a clinician decanting a male product. The gap between the single consensus-supported indication and the range of benefits marketed is the widest of any term in this branch, and it is the main reason the evidence tier here is emerging rather than well-evidenced.
Offered across the Atlas 5
Related modalities